Get the Stockscreener App
51.89
5.67%
2.785
Spruce Biosciences Inc stock is traded at $51.89, with a volume of 80,927.
It is up +5.67% in the last 24 hours and down -8.43% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
See More
Previous Close:
$49.10
Open:
$49.18
24h Volume:
80,927
Relative Volume:
1.32
Market Cap:
$142.82M
Revenue:
$697.00K
Net Income/Loss:
$-37.19M
P/E Ratio:
-1.3766
EPS:
-37.6952
Net Cash Flow:
$-29.34M
1W Performance:
+2.90%
1M Performance:
-8.43%
6M Performance:
-37.78%
1Y Performance:
-90.34%
1-Day Range:
$49.02
$53.25
1-Week Range:
$46.50
$53.25
52-Week Range:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
51.89 | 142.82M | 697.00K | -37.19M | -29.34M | -37.70 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Craig Hallum | Buy |
| Dec-23-25 | Initiated | Oppenheimer | Outperform |
| Dec-03-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-28-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
SPRB Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Jones Trading initiates Spruce Biosciences stock with buy rating on therapy potential By Investing.com - Investing.com Australia
Spruce Biosciences (SPRB) Reports Promising Long-Term Results fo - GuruFocus
Jones Trading initiates Spruce Biosciences stock with buy rating on therapy potential - Investing.com UK
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B Presented at the 18th International MPS Symposium - Investing News Network
Spruce says long-term TA-ERT data presented at MPS Symposium - TipRanks
Spruce Biosciences stock rises on MPS IIIB data, analyst initiation - Investing.com
Spruce Biosciences stock rises on MPS IIIB data, analyst initiation By Investing.com - Investing.com Canada
Spruce Biosciences (SPRB) Reports Promising Long-Term Results for Enzyme Therapy - GuruFocus
Spruce presents six-year data on MPS IIIB therapy candidate By Investing.com - Investing.com South Africa
Spruce presents six-year data on MPS IIIB therapy candidate - Investing.com
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium - Business Wire
SPRB News | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Spruce Biosciences (SPRB) Edges Lower Amid Consolidation PhaseChart Pattern Alerts - newsline.com
SPRB Technical Analysis | Trend, Signals & Chart Patterns | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Spire Global, Inc. (SPIR) Is Up 7.94% in One Week: What You Should Know - Yahoo Finance
H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $150 - Moomoo
SPRB Maintains Buy Rating by HC Wainwright & Co. -- Price Target Lowered to $150 - GuruFocus
Spruce Biosciences price target lowered to $150 from $200 at H.C. Wainwright - TipRanks
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium - BioSpace
Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium - TradingView
Spruce Biosciences to Participate in Upcoming Conferences in June 2026 - BioSpace
Spruce Biosciences to Participate in Upcoming Conferences in June - Investing News Network
Spruce Biosciences Stockholders Approve Directors and Annual Say-on-Pay - The Globe and Mail
Oppenheimer Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $230 - Moomoo
Oppenheimer lowers Spruce Biosciences stock price target to $230 By Investing.com - Investing.com South Africa
Oppenheimer lowers Spruce Biosciences stock price target to $230 - Investing.com
Spruce Biosciences (SPRB) director granted 1,700 stock options at 52.70 - Stock Titan
Director Camilla V. Simpson awarded 1,700 SPRB options at $52.70 strike - Stock Titan
Spruce Biosciences (SPRB) chair receives grant of 1,700 stock options - Stock Titan
Spruce Biosciences (NASDAQ: SPRB) grants director 1,700 options - Stock Titan
Spruce Biosciences (SPRB) grants director Keli Walbert 1,700 options - Stock Titan
Spruce Biosciences (SPRB) 2026 annual meeting and say-on-pay votes - Stock Titan
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy - Yahoo Finance
Spruce Biosciences Inc (SPRB) Stock Price, Quote, News & History - Benzinga
SPRB: Directors elected, all proposals approved, and strategic plans funded for regulatory milestones - TradingView
SPRB: All proposals passed, with updates on financing, manufacturing, and regulatory milestones shared - TradingView
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade - MSN
Is Spruce Biosciences (SPRB) Overvalued After Q1 2026 EPS Beat? - GuruFocus
Citadel entities, Kenneth Griffin hold ~5.1% of Spruce Biosciences (SPRB) - Stock Titan
Alyeska Group (SPRB) discloses 61,670-share position, 4.49% of float - Stock Titan
Leerink Partners Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $120 - Moomoo
Squadron entities report 12,200 SPRB shares (0.9%) — SPRB - Stock Titan
Wellington Group discloses 48,796 shared dispositive shares in Spruce Biosciences (NASDAQ: SPRB) - Stock Titan
SPRB Maintains by Citizens -- Price Target Lowered to $150 - GuruFocus
Spruce Biosciences 1Q Research and Development Expenses $7.6M >SPRB - Moomoo
Spruce Biosciences, Inc. Stock 12‑Month Price Target Cut to $178.6, Implies 210% Upside - TradingView
Spruce Biosciences Is Maintained at Market Outperform by Citizens - Moomoo
Spruce Biosciences price target lowered to $150 from $170 at Citizens - TipRanks
Citizens lowers Spruce Biosciences stock price target on model update By Investing.com - Investing.com Nigeria
Citizens lowers Spruce Biosciences stock price target on model update - Investing.com
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):